Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma

By: Lauren Harrison, MD, MS
Posted: Wednesday, June 8, 2022

Patients with relapsed or refractory multiple myeloma treated with a single infusion of ciltacabtagene autoleucel had deep and durable responses after 2 years, according to Saad Zafar Usmani, MD, MBA, of Memorial Sloan Kettering Cancer Center, New York, and colleagues. Ciltacabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy with two single-domain antibodies that target B-cell maturation antigens (BCMAs). This update from the CARTITUDE-1 trial was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8028).

This phase Ib/II trial enrolled 97 patients with multiple myeloma who had received either three or more prior lines of therapy or were refractory to a proteasome inhibitor or an immunomodulatory drug. This cohort had been exposed to a median of six prior lines of therapy, and 84% of patients had been exposed to five drugs before enrollment. Patients underwent lymphodepletion, then received a single infusion of ciltacabtagene autoleucel at a target dose of 0.75 x 106 CAR-positive viable T cells/kg.

At 21.7 months of follow-up, the overall response rate was 97.9%, with 94.9% of patients achieving a very good partial response and 82.5% achieving a stringent complete response. This is an improvement from the 1-year follow-up, at which the overall response rate was 97% and the stringent complete response rate was 67%. There were 61 patients evaluable for measurable residual disease (MRD), and 92% of these patients achieved MRD negativity; it was sustained for 6 months or more in 44% of patients and for more than 12 months in 18%. The 2-year progression-free survival rate in patients with sustained MRD activity for 6 months was 91% and 100% in those who sustained MRD negativity for 12 months.

Since the 1-year follow-up, there were no new safety signals or events related to CAR T-cell therapy. However, there were 15 second primary malignancies reported in 11 patients over the 2-year follow-up.

Disclosures: For a full list of authors’ disclosures, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.